TW202334136A - PI3Kα抑制劑及其製造與使用方法 - Google Patents
PI3Kα抑制劑及其製造與使用方法 Download PDFInfo
- Publication number
- TW202334136A TW202334136A TW111141786A TW111141786A TW202334136A TW 202334136 A TW202334136 A TW 202334136A TW 111141786 A TW111141786 A TW 111141786A TW 111141786 A TW111141786 A TW 111141786A TW 202334136 A TW202334136 A TW 202334136A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- iii
- formula
- solid
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263474P | 2021-11-03 | 2021-11-03 | |
| WOPCT/CN2021/128533 | 2021-11-03 | ||
| US63/263,474 | 2021-11-03 | ||
| CN2021128533 | 2021-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202334136A true TW202334136A (zh) | 2023-09-01 |
Family
ID=86242193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111141786A TW202334136A (zh) | 2021-11-03 | 2022-11-02 | PI3Kα抑制劑及其製造與使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4426314A4 (https=) |
| JP (1) | JP2024540303A (https=) |
| KR (1) | KR20240112283A (https=) |
| CN (1) | CN118401245A (https=) |
| AU (1) | AU2022381187A1 (https=) |
| CA (1) | CA3236861A1 (https=) |
| CL (1) | CL2024001364A1 (https=) |
| IL (1) | IL312466A (https=) |
| MX (1) | MX2024005429A (https=) |
| PE (1) | PE20250676A1 (https=) |
| TW (1) | TW202334136A (https=) |
| WO (1) | WO2023081757A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4143196A4 (en) | 2020-04-29 | 2024-04-17 | Relay Therapeutics, Inc. | PI3K-A INHIBITORS AND METHODS OF USE THEREOF |
| WO2024055992A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京再明医药有限公司 | 三环化合物及其应用 |
| TW202541794A (zh) | 2022-11-02 | 2025-11-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點 |
| KR20260005985A (ko) | 2023-05-05 | 2026-01-12 | 일라이 릴리 앤드 캄파니 | Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| PE20161323A1 (es) * | 2013-09-05 | 2016-11-25 | Hoffmann La Roche | Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos |
| WO2017000277A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2020173935A1 (en) * | 2019-02-26 | 2020-09-03 | Boehringer Ingelheim International Gmbh | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| EP4143196A4 (en) * | 2020-04-29 | 2024-04-17 | Relay Therapeutics, Inc. | PI3K-A INHIBITORS AND METHODS OF USE THEREOF |
-
2022
- 2022-11-02 TW TW111141786A patent/TW202334136A/zh unknown
- 2022-11-03 AU AU2022381187A patent/AU2022381187A1/en active Pending
- 2022-11-03 PE PE2024001004A patent/PE20250676A1/es unknown
- 2022-11-03 KR KR1020247018494A patent/KR20240112283A/ko active Pending
- 2022-11-03 CA CA3236861A patent/CA3236861A1/en active Pending
- 2022-11-03 IL IL312466A patent/IL312466A/en unknown
- 2022-11-03 MX MX2024005429A patent/MX2024005429A/es unknown
- 2022-11-03 EP EP22891040.2A patent/EP4426314A4/en active Pending
- 2022-11-03 JP JP2024526614A patent/JP2024540303A/ja active Pending
- 2022-11-03 CN CN202280082873.4A patent/CN118401245A/zh active Pending
- 2022-11-03 WO PCT/US2022/079221 patent/WO2023081757A1/en not_active Ceased
-
2024
- 2024-05-03 CL CL2024001364A patent/CL2024001364A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3236861A1 (en) | 2023-05-11 |
| JP2024540303A (ja) | 2024-10-31 |
| EP4426314A4 (en) | 2025-10-01 |
| WO2023081757A1 (en) | 2023-05-11 |
| KR20240112283A (ko) | 2024-07-18 |
| EP4426314A1 (en) | 2024-09-11 |
| AU2022381187A1 (en) | 2024-05-16 |
| CN118401245A (zh) | 2024-07-26 |
| PE20250676A1 (es) | 2025-03-04 |
| IL312466A (en) | 2024-06-01 |
| CL2024001364A1 (es) | 2024-10-25 |
| MX2024005429A (es) | 2024-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3224985C (en) | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | |
| TW202334136A (zh) | PI3Kα抑制劑及其製造與使用方法 | |
| WO2023060262A1 (en) | Pi3k-alpha inhibitors and methods of use thereof | |
| JP6980649B2 (ja) | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 | |
| TW200806664A (en) | Azaindoles useful as inhibitors of janus kinases | |
| TW202233625A (zh) | Ｆｇｆｒ抑制劑及其製造及使用方法 | |
| CA2879400A1 (en) | Deuterated ibrutinib | |
| WO2019189732A1 (ja) | 光学活性な架橋型環状２級アミン誘導体 | |
| JP2024051160A (ja) | ピリミジン誘導体の医薬塩及び障害の処置方法 | |
| CN119486992A (zh) | PI3Kα抑制剂及其使用方法 | |
| CN118201896A (zh) | PI3K-α抑制剂和其使用方法 | |
| JP2021500366A (ja) | 置換されているイミダゾピリジンアミド類及びそれらの使用 | |
| EP4426286A1 (en) | Bifunctional pi3k-alpha inhibitors and uses thereof | |
| JP7781327B2 (ja) | 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤 | |
| JP2022521491A (ja) | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 | |
| EP3101020B1 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
| EP3730492A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof | |
| TW202527954A (zh) | PI3Kα抑制劑及其製造與使用方法 | |
| US20260125374A1 (en) | Pi3k-alpha inhibitors and methods of making and using the same | |
| CN120676939A (zh) | Pi3k抑制剂及其制备和使用方法 | |
| CN118251217A (zh) | PI3Kα抑制剂及其使用方法 | |
| EA051309B1 (ru) | Ингибиторы pi3k-альфа и способы их получения и использования | |
| WO2026044398A1 (en) | Salts of 5-chloro-2-fluoro-n-(2-fluoro-4-(3-methyl-4-[(1-methylpiperidin-4-yl)oxy]-1h-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)benzene sulfonamide and crystalline forms thereof | |
| CN118126051A (zh) | 突变体braf降解剂的多晶型物及其制备方法 | |
| NZ743251A (en) | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |